4.7 Article

Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation

期刊

KIDNEY INTERNATIONAL
卷 76, 期 6, 页码 659-664

出版社

ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2009.236

关键词

access to care; deceased donor; indigenous health; living donor; renal failure; renal transplantation

向作者/读者索取更多资源

In Australia, Canada, New Zealand, and the United States indigenous people have high rates of chronic kidney disease but poor access to effective therapies. To more fully define these issues, we compared the demographics of renal transplantation of indigenous patients in these 4 countries. Data encompassing 312,507 indigenous and white patients (18-64 years of age) who initiated dialysis within an 11-year period ending in 2005 were obtained from each country's end-stage kidney disease registry. By the study's end, 88,173 patients had received a renal transplant and 130,261 had died without receiving such. Compared with white patients, the adjusted likelihood of receiving a transplant for indigenous patients was significantly lower in Australia (hazard ratio (HR) 0.23), Canada (HR 0.34), New Zealand (HR 0.23), and the United States (HR 0.44). In all four countries, indigenous patients had significantly longer overall median waiting times compared to white patients. Our study shows that despite marked differences in health care delivery systems, indigenous patients are less likely than white patients to receive a renal transplant in these countries. Understanding and addressing barriers to renal transplantation of indigenous patients remains an important concern.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, General & Internal

Retrospective case-control study exploring pretransplant predictors for loss of kidney transplant function or death among indigenous kidney transplant recipients

Namrata Khanal, Paul D. Lawton, Alan Cass, Stephen P. McDonald

INTERNAL MEDICINE JOURNAL (2023)

Article Pharmacology & Pharmacy

Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial

Amy Legg, Niamh Meagher, Sandra A. Johnson, Matthew A. Roberts, Alan Cass, Marc H. Scheetz, Jane Davies, Jason A. Roberts, Joshua S. Davis, Steven Y. C. Tong

Summary: The clinical risk factors for nephrotoxicity in Staphylococcus aureus bacteraemia are still unclear. In a clinical trial comparing standard therapy to combination therapy, it was found that the combination therapy group had a significantly higher incidence of acute kidney injury.

CLINICAL DRUG INVESTIGATION (2023)

Review Urology & Nephrology

Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review

Benjamin Talbot, Alan Cass, Robert Walker, Lai Hooi, Meg Jardine, Min Jun, Kris Rogers, Louisa Sukkar, Brendan Smyth, Martin Gallagher

Summary: This study examined whether there were differences in survival and causes of death among participants from Australia, Malaysia, and New Zealand in the extended follow-up of the SHARP study. It was found that participants from Malaysia and New Zealand had a higher risk of death compared to participants from Australia.

NEPHROLOGY (2023)

Article Cardiac & Cardiovascular Systems

Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study

Min Jun, Anish Scaria, Jason Andrade, Sunil Badve, Peter Birks, Sarah E. Bota, Anna Campain, Ognjenka Djurdjev, Amit X. Garg, Jeffrey Ha, Ziv Harel, Brenda Hemmelgarn, Carinna Hockham, Matthew T. James, Meg J. Jardine, Adeera Levin, Eric McArthur, Pietro Ravani, Selena Shao, Manish M. Sood, Zhi Tan, Navdeep Tangri, Reid Whitlock, Martin Gallagher

Summary: This study found that the use of DOACs in atrial fibrillation patients was associated with a lower or similar risk of all-cause death, ischemic stroke, and major bleeding compared to the use of warfarin, regardless of kidney function levels.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2023)

Article Urology & Nephrology

Sex and Gender in Randomized Controlled Trials of Adults Receiving Maintenance Dialysis: A Meta-epidemiologic Study

David Collister, Lonnie Pyne, Arrti A. Bhasin, Sotla B. Ahmed, Brendan Smyth, William Herrington, Meg Jardine, Michael Walsh

Summary: This study investigates how sex and gender concepts are incorporated into randomized controlled trials (RCTs) in adults with kidney failure receiving maintenance dialysis. The results show that most RCTs only report either sex or gender, with few studies including both in their reporting and analysis.

AMERICAN JOURNAL OF KIDNEY DISEASES (2023)

Article Endocrinology & Metabolism

Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

Akihiko Koshino, Megumi Oshima, Clare Arnott, Robert A. Fletcher, George L. Bakris, Meg Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Carol Pollock, Hiddo J. L. Heerspink, Brendon L. Neuen

DIABETES OBESITY & METABOLISM (2023)

Article Orthopedics

Hip Arthroplasty Outcomes in the Presence of Kidney Failure: A National Data Linkage Study

Ian A. Harris, Michelle F. Lorimer, Christopher E. Davies, Dominic Keuskamp, Kathryn B. Dansie, Peter L. Lewis, Stephen E. Graves, Stephen P. McDonald

Summary: This study compared the rate of revision surgery and mortality following THA between patients who have kidney failure receiving long term dialysis or who had a kidney transplant and those who did not have kidney failure. The results showed that patients on dialysis had a higher risk of mortality after THA compared to those with a functioning kidney transplant or no kidney failure, but there was no early excess mortality due to the surgery.

JOURNAL OF ARTHROPLASTY (2023)

Article Medicine, General & Internal

Prognostic Significance of Baseline Blood Glucose Levels and Glucose Variability in Severe Acute Kidney Injury: A Secondary Analysis from the RENAL Study

Ying Xie, Jin Lin, Martin Gallagher, Rinaldo Bellomo, Xia Wang, Meg Jardine, Meili Duan, Amanda Wang

Summary: This study aimed to investigate the associations between baseline blood glucose levels (BGL), glycemic variability, and clinical outcomes in severe acute kidney injury (AKI) patients receiving continuous renal replacement therapy (CRRT). The findings suggest that low baseline BGL within the normal physiological range and higher glycemic variability are significant modifiable risk factors for mortality in ICU patients with severe AKI.

JOURNAL OF CLINICAL MEDICINE (2023)

Letter Anesthesiology

The impact of dexmedetomidine on postoperative delirium: should we throw out a DECADE of research?

Thomas Payne, Mark Coburn, Stefan Dieleman, Gillian Heller, Meg Jardine, Yahya Shehabi, Robert D. Sanders

BRITISH JOURNAL OF ANAESTHESIA (2023)

Article Urology & Nephrology

Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR A Post Hoc Analysis of the CREDENCE Trial

Sjoukje van der Hoek, Niels Jongs, Megumi Oshima, Brendon L. L. Neuen, Jasper Stevens, Vlado Perkovic, Adeera Levin, Kenneth W. W. Mahaffey, Carol Pollock, Tom Greene, David C. C. Wheeler, Meg J. J. Jardine, Hiddo J. L. Heerspink

Summary: In the CREDENCE trial, canagliflozin was found to have a greater impact on eGFR slope in patients with higher baseline HbA1c levels, indicating that patients with poorer glycemic control may benefit more from the drug.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Endocrinology & Metabolism

The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

Amy Kang, Brendan Smyth, Brendon L. L. Neuen, Hiddo J. L. Heerspink, Gian Luca Di Tanna, Hong Zhang, Clare Arnott, Carinna Hockham, Rajiv Agarwal, George Bakris, David M. M. Charytan, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C. C. Wheeler, Kenneth W. W. Mahaffey, Vlado Perkovic, Meg J. J. Jardine

Summary: The aim of this study was to assess the risk of non-genital skin and soft tissue infections (SSTIs) associated with the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin. A post hoc analysis of two trials was conducted, and the results showed that canagliflozin did not significantly affect the risk of non-genital SSTIs or non-genital fungal SSTIs compared with placebo. This suggests that the changes in skin microenvironment mediated by SGLT2 inhibitors may not have meaningful clinical consequences.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

David M. Charytan, Kenneth W. Mahaffey, Meg J. Jardine, Christopher P. Cannon, Bruce Neal, Hiddo J. Lambers Heerspink, Rajiv Agarwal, George L. Bakris, Dick de Zeeuw, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Norman Rosenthal, Vlado Perkovic, Gian Luca Di Tanna, Jie Yu, Kris Rogers, Clare Arnott, David C. Wheeler

Summary: The relationship between the glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and their impact on kidney and cardiovascular outcomes remains uncertain. This study analyzed the effects of canagliflozin on hemoglobin A1c (HbA1c) in individuals with diabetes and the mediation of glycemic control on treatment outcomes. The results showed that the glycemic effects of canagliflozin were attenuated at lower estimated glomerular filtration rate (eGFR), but its effects on kidney and cardiovascular outcomes were preserved.

BMJ OPEN DIABETES RESEARCH & CARE (2023)

Article Urology & Nephrology

Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

Robert A. Fletcher, Niels Jongs, Glenn M. Chertow, John J. V. Mcmurray, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Patrick Rockenschaub, Peter Rossing, Ricardo Correa-Rotter, Robert D. Toto, Muthiah Vaduganathan, David C. Wheeler, Hiddo J. L. Heerspink, Brendon L. Neuen

Summary: This study analyzed the effect of SGLT2 inhibitors on the discontinuation of RAS blockade and found that patients receiving SGLT2 inhibitors had a lower risk of discontinuing RAS blockade. This effect was particularly pronounced in patients with a high baseline urinary albumin-to-creatinine ratio.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Biology

The Diagnostic Performance of a Clinical Diagnosis of Diabetic Kidney Disease

Ken-Soon Tan, Stephen McDonald, Wendy Hoy

Summary: This study compared the performance of a clinical diagnosis to biopsy-proven diagnosis of diabetic kidney disease (DKD) and found that a clinical diagnosis has high sensitivity but low specificity, indicating the possibility of overdiagnosis.

LIFE-BASEL (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL

Sneha S. Jain, Jie Yu, Clare Arnott, Bruce Charles Neal, Vlado Perkovic, Brendon Neuen, Meg Jardine, Kenneth W. Mahaffey

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

暂无数据